Wedbush Issues Positive Forecast for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price objective lifted by Wedbush from $29.00 to $30.00 in a report published on Wednesday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock.

Several other brokerages also recently issued reports on DAWN. TD Cowen began coverage on Day One Biopharmaceuticals in a research report on Tuesday, January 13th. They set a “buy” rating and a $34.00 price objective for the company. HC Wainwright dropped their price target on Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a research report on Wednesday. JPMorgan Chase & Co. boosted their price target on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Needham & Company LLC reduced their price objective on Day One Biopharmaceuticals from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Piper Sandler increased their price objective on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Day One Biopharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $26.14.

Day One Biopharmaceuticals Stock Down 9.1%

Day One Biopharmaceuticals stock opened at $10.93 on Wednesday. The firm has a market capitalization of $1.12 billion, a PE ratio of -10.61 and a beta of -1.26. Day One Biopharmaceuticals has a 52 week low of $5.64 and a 52 week high of $13.20. The firm’s 50-day simple moving average is $10.67 and its 200 day simple moving average is $8.76.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative return on equity of 23.14% and a negative net margin of 67.85%.The business had revenue of $53.72 million for the quarter, compared to analyst estimates of $49.81 million. On average, research analysts expect that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Activity at Day One Biopharmaceuticals

In related news, CFO Charles N. York II sold 6,065 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $70,354.00. Following the transaction, the chief financial officer directly owned 312,025 shares in the company, valued at approximately $3,619,490. This represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jeremy Bender sold 15,459 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $179,324.40. Following the completion of the sale, the chief executive officer directly owned 204,603 shares in the company, valued at approximately $2,373,394.80. The trade was a 7.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 36,461 shares of company stock worth $422,948. Company insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several hedge funds have recently modified their holdings of DAWN. Invesco Ltd. grew its holdings in Day One Biopharmaceuticals by 26.5% in the fourth quarter. Invesco Ltd. now owns 123,994 shares of the company’s stock valued at $1,156,000 after purchasing an additional 25,952 shares during the period. Oracle Investment Management Inc. purchased a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at $932,000. XTX Topco Ltd increased its holdings in shares of Day One Biopharmaceuticals by 62.9% during the 4th quarter. XTX Topco Ltd now owns 128,440 shares of the company’s stock worth $1,197,000 after buying an additional 49,592 shares during the last quarter. VARCOV Co. purchased a new position in shares of Day One Biopharmaceuticals in the 4th quarter worth $261,000. Finally, Vestal Point Capital LP boosted its holdings in Day One Biopharmaceuticals by 94.4% in the fourth quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock valued at $48,464,000 after acquiring an additional 2,525,000 shares during the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat and product momentum: Day One reported Q4 net product revenue that topped estimates and highlighted OJEMDA™ momentum and record revenue growth for 2025. Article Title
• Positive Sentiment: Company reaffirmed 2026 outlook and guidance: Day One reiterated 2026 U.S. net product revenue guidance of $225–$250M and disclosed the January acquisition of Mersana to expand its pipeline. Article Title
• Positive Sentiment: Analyst uplift from Wedbush: Wedbush raised its price target sharply to $30 and keeps an outperform rating, signaling at least one broker sees substantial upside vs. the current price. Article Title
• Neutral Sentiment: Other analysts trimmed targets but kept buy ratings: Needham cut its target to $17 and HC Wainwright trimmed to $22, yet both maintain positive ratings — a mixed signal on near-term valuation. Article Title
• Neutral Sentiment: Full earnings materials and transcripts available: The earnings slide deck and call transcript are posted for investors to review management commentary and guidance details. Article Title
• Neutral Sentiment: Short-interest data unclear: February short-interest reporting here shows effectively 0 shares (data appears inconsistent/NaN); no clear short-squeeze signal from the published short-interest figures.
• Negative Sentiment: EPS miss pressures sentiment: Reported EPS came in at ($0.21), missing the consensus of ($0.17); that earnings shortfall helps explain the stock selling off despite the revenue beat. Article Title

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.